BIOHAVEN PHARMACTL HLDG CO L's ticker is BHVN and the CUSIP is G11196105. A total of 106 filers reported holding BIOHAVEN PHARMACTL HLDG CO L in Q2 2018. The put-call ratio across all filers is 0.13 and the average weighting 0.7%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2022 | $137,000 | -67.3% | 43,200 | +11.3% | 0.01% | -50.0% |
| Q4 2021 | $419,000 | -87.9% | 38,800 | -90.1% | 0.01% | -88.0% |
| Q4 2020 | $3,465,000 | +368.9% | 391,600 | +127.8% | 0.10% | +177.8% |
| Q3 2020 | $739,000 | -64.5% | 171,900 | +14.5% | 0.04% | -68.4% |
| Q2 2020 | $2,080,000 | +12135.3% | 150,100 | +63.0% | 0.11% | +11300.0% |
| Q1 2020 | $17,000 | -99.7% | 92,100 | -44.0% | 0.00% | -99.6% |
| Q4 2019 | $5,072,000 | +435.6% | 164,452 | -30.6% | 0.28% | +256.4% |
| Q3 2019 | $947,000 | +25.4% | 236,899 | -24.1% | 0.08% | +34.5% |
| Q2 2019 | $755,000 | +568.1% | 312,300 | +266.5% | 0.06% | +480.0% |
| Q1 2019 | $113,000 | -79.2% | 85,200 | +69.6% | 0.01% | -63.0% |
| Q1 2018 | $542,000 | – | 50,247 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RP Management, LLC | 2,111,111 | $144,294,000 | 54.16% |
| Knoll Capital Management, LLC | 856,844 | $58,565,000 | 38.16% |
| ORACLE INVESTMENT MANAGEMENT INC | 2,123,271 | $145,126,000 | 21.73% |
| KINGDON CAPITAL MANAGEMENT, L.L.C. | 860,261 | $58,799,000 | 6.01% |
| ARS Investment Partners, LLC | 561,442 | $38,375,000 | 4.46% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 176,400 | $12,057,000 | 3.19% |
| Eventide Asset Management | 2,015,000 | $137,725,000 | 2.04% |
| Avidity Partners Management LP | 1,049,800 | $71,754,000 | 1.98% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 50,089 | $3,424,000 | 1.87% |
| Nicholas Investment Partners, LP | 375,654 | $25,676,000 | 1.79% |